Biopure Corporation

Jul 17, 09
	NEW STORY
15:30 ET	Biopure Corporation Receives Notice of Delisting from Nasdaq
Jul 16, 09
	NEW STORY
17:00 ET	Biopure Files Voluntary Petition for Relief Under Chapter 11 of the United States Bankruptcy Code
Jun 30, 09
08:30 ET	Biopure Receives Notice of Nasdaq Delisting
May 18, 09
08:00 ET	U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold
Mar 31, 09
15:00 ET	Biopure Receives Notices About Nasdaq Listing Compliance
Mar 23, 09
07:30 ET	U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'RESUS' Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
Feb 17, 09
14:59 ET	Biopure Exploring Strategic Options
Dec 30, 08
17:00 ET	Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
17:00 ET	U.S. Navy Requested Operations Trial on FDA Hold
Dec 17, 08
08:35 ET	Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
Dec 02, 08
17:30 ET	U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting
Oct 28, 08
16:15 ET	Agency Takes Adverse Decision to Biopure's Product Registration in South Africa
16:05 ET	Biopure Sues National Institutes of Health Official
08:30 ET	Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
Aug 21, 08
16:15 ET	Biopure Announces 2008 Third Quarter Financial Results
Jul 07, 08
07:49 ET	Biopure Announces Meeting With FDA
Jul 02, 08
16:18 ET	Biopure Announces Private Equity Financing
Jun 18, 08
16:15 ET	U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
Jun 12, 08
16:30 ET	Biopure Granted Additional 180 Day Compliance Period by NASDAQ
Jun 10, 08
16:35 ET	Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma
Jun 09, 08
08:08 ET	Biopure Responds to JAMA and Meta-Analysis
Jun 05, 08
10:24 ET	Biopure Announces MHRA Meeting Update
May 21, 08
17:30 ET	Biopure Announces 2008 Second Quarter Financial Results
May 19, 08
08:30 ET	Biopure Wins European Patent Challenge
May 14, 08
16:35 ET	Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
08:30 ET	Biopure Appoints Dechra Exclusive U.S. Distributor of Oxyglobin
May 08, 08
08:30 ET	U.S. Navy Receives Funding for Further Development of Hemopure(R)
May 07, 08
09:49 ET	Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
May 02, 08
14:11 ET	Biopure Announces Date to Meet with UK's Medicines and Healthcare Products Agency
Apr 11, 08
08:00 ET	Biopure Operations Compliant With U.K. Manufacturing Guidelines
Apr 10, 08
08:00 ET	Biopure Appoints New Independent Auditor
Apr 07, 08
07:00 ET	Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
Mar 19, 08
16:50 ET	Biopure Completes U.K. Regulatory Agency Inspection
Feb 26, 08
09:46 ET	Biopure Announces 2008 First Quarter Financial Results
Feb 21, 08
16:30 ET	Biopure Announces 2008 First Quarter Financial Results
Feb 04, 08
07:00 ET	Biopure Launches Updated Website
Jan 28, 08
18:16 ET	Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
Dec 20, 07
07:30 ET	Biopure Appoints David A. Butler Interim CFO
07:30 ET	Biopure Receives Notice of NASDAQ Listing Requirements
Dec 04, 07
12:16 ET	Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
Nov 08, 07
07:00 ET	Biopure Submits Complete Response to U.K. Regulatory Body on Marketing Application for Hemopure(R)
Nov 06, 07
16:10 ET	Biopure Announces Closing of $14.9 Million Financing
Nov 01, 07
07:00 ET	Biopure Announces Pricing of Equity Offering
Oct 31, 07
07:00 ET	Biopure's Stock Symbol Reverts to BPUR
Oct 17, 07
07:30 ET	Biopure Appoints Officer and Regains Nasdaq Listing Compliance
Oct 15, 07
08:02 ET	Biopure Announces Expanded Clinical Program To Target Anemia
Oct 02, 07
07:00 ET	Biopure Announces Reverse Stock Split
Sep 06, 07
07:00 ET	Biopure Reports on Meeting with the FDA
Aug 23, 07
17:22 ET	Biopure Announces 2007 Third Quarter Financial Results
16:54 ET	Biopure Announces 2007 Third Quarter Financial Results
08:45 ET	Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
Aug 22, 07
15:08 ET	Biopure Gives Update on Malaysia Joint Venture Discussions
Jul 25, 07
14:49 ET	Biopure Announces Recent Progress
14:27 ET	Biopure Announces Recent Progress
May 17, 07
16:54 ET	Biopure Announces 2007 Second Quarter Financial Results
Apr 20, 07
17:14 ET	Biopure Moves to Nasdaq Capital Market
Apr 09, 07
06:30 ET	Biopure Appoints Allan Ferguson to Its Board of Directors
Feb 15, 07
16:05 ET	Biopure Announces 2007 First Quarter Financial Results
Jan 10, 07
16:10 ET	Biopure Provides Further Comment on U.K. Regulatory Body Letter Regarding Marketing Application for Hemopure(R)
06:30 ET	Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
Dec 20, 06
06:15 ET	Biopure Announces Next Steps for Navy's Proposed 'Resus' Trauma Trial of Hemopure(R)
Dec 15, 06
06:00 ET	FDA Panel Recommends Navy's Proposed 'RESUS' Phase IIb/III Trauma Trial Not Proceed as Designed; Suggests Phase II Study
Dec 14, 06
06:10 ET	Biopure Announces 2006 Fourth Quarter and Year-End Financial Results and Closing of $16.6 Million Financing
Dec 08, 06
06:00 ET	Biopure Announces Pricing of Equity Offering
Nov 29, 06
13:35 ET	FDA Advisory Committee to Consider Navy's Proposed 'Resus' Trauma Trial in Open Session on December 14, 2006
Nov 07, 06
07:00 ET	Biopure's Phase II Trauma Trial of Hemopure(R) in South Africa Continues Following Independent Panel's First Scheduled Interim Review
Oct 18, 06
16:10 ET	Biopure Receives Notice of Nasdaq Listing Requirements
Sep 12, 06
16:01 ET	Biopure Announces Final Settlement of SEC Litigation
07:00 ET	Biopure's Marketing Application for Hemopure(R) Accepted for Review In United Kingdom
Aug 17, 06
17:53 ET	Biopure Announces 2006 Third Quarter Financial Results and $5.0 Million Financing
Jul 14, 06
17:38 ET	Biopure Statement on Cancellation of FDA Advisory Committee Meeting
Jul 12, 06
17:28 ET	Biopure Comments on Wall Street Journal Articles
Jul 11, 06
07:00 ET	Biopure Applies for Marketing Authorization of Hemopure(R) In the United Kingdom
Jun 07, 06
07:00 ET	Biopure To Present At the Wall Street Analyst Forum - Analyst Conference On June 14, 2006
May 26, 06
07:00 ET	FDA Advisory Committee to Consider Navy's Proposed 'RESUS' Trauma Trial at July 2006 Meeting
May 18, 06
07:00 ET	Biopure Announces 2006 Second Quarter Financial Results
May 15, 06
07:00 ET	Biopure Appoints Vice President of Medical Affairs
Mar 21, 06
09:09 ET	Biopure Regains Nasdaq Listing Compliance
Mar 13, 06
16:13 ET	Biopure Reaches Agreement in Principle with SEC Staff for Settlement of Litigation
10:38 ET	FDA to Consult Scientific Advisory Committee on Navy's Proposed 'RESUS' Trauma Trial
Feb 16, 06
07:01 ET	Biopure Announces 2006 First Quarter Financial Results
Jan 30, 06
07:00 ET	Biopure Begins Selling Hemopure(R) in South Africa
Jan 17, 06
16:01 ET	Biopure Announces Closing of $3.0 Million Financing
Jan 11, 06
07:01 ET	Biopure to Apply for European Marketing Approval of Hemopure(R) in 2006
Jan 04, 06
07:00 ET	Biopure to Initiate Marketing and Sales of Hemopure(R) in South Africa With New Sales Agent
Jan 03, 06
09:27 ET	U.S. Navy to Receive Defense Appropriation for Hemopure(R) Research and Development
Dec 28, 05
12:07 ET	Biopure Announces Closing of $5.8 Million Financing
Dec 21, 05
07:00 ET	Biopure Announces Pricing of Equity Offering
Dec 19, 05
16:24 ET	Biopure Receives Notice of Nasdaq Listing Requirements
Dec 15, 05
11:31 ET	Biopure Announces 2005 Fourth Quarter and Year-End Financial Results
Dec 01, 05
16:19 ET	Biopure Announces Proposed Public Offering of Common Stock
Nov 30, 05
08:45 ET	Biopure Updates Regulatory Status of Navy's Proposed 'RESUS' Trauma Trial
Nov 02, 05
07:15 ET	Clinical Trial of Hemopure(R) in Lower Limb Amputation Receives U.K. Regulatory Authorization to Proceed
Oct 27, 05
16:12 ET	Biopure to Present at Mass Opportunities and Rodman & Renshaw Techvest Investor Conferences
07:05 ET	U.K. Regulatory Body Authorizes Proposed Clinical Trial of Hemopure(R) in Cardiac Surgery
Oct 19, 05
07:15 ET	Biopure Provides Clinical Development Update for Hemopure(R)
Sep 14, 05
17:42 ET	Biopure Announces Filing of SEC Suit
Sep 06, 05
07:15 ET	Biopure Announces Resignation of Carl Rausch From Board of Directors and Chief Technology Officer Position
Aug 29, 05
07:15 ET	Biopure Appoints Guido J. Neels to its Board of Directors
Aug 18, 05
07:15 ET	Biopure Announces 2005 Third Quarter Financial Results
Jul 12, 05
07:01 ET	U.S. Navy's IND For Proposed 'RESUS' Trauma Trial on Hold Pending Response to FDA
Jul 06, 05
07:00 ET	Biopure to Present at C.E. Unterberg Towbin Emerging Growth Opportunities Conference on July 13, 2005
Jun 27, 05
18:04 ET	Biopure's Stock Symbol Reverts to BPUR
Jun 15, 05
07:01 ET	Biopure Regains Nasdaq Listing Compliance
Jun 13, 05
06:55 ET	U.S. Navy Seeks FDA Okay to Start Trauma Trial of Hemopure(R)
May 27, 05
12:47 ET	Biopure Corporation Announces Post Reverse Stock Split Trading to Begin May 31, 2005
06:00 ET	Biopure Corporation Completes Previously Announced Reverse Stock Split
May 19, 05
16:11 ET	Biopure Announces 2005 Second Quarter Financial Results and Board Approval of Reverse Stock Split
May 02, 05
18:27 ET	Biopure to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference on May 4, 2005
Apr 27, 05
08:16 ET	Biopure to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference on May 4, 2005
Apr 06, 05
07:30 ET	Biopure Completes Patient Enrollment in European Phase 2 Clinical Trial of Hemopure(R) in Coronary Angioplasty Patients
Feb 17, 05
07:33 ET	Biopure Announces 2005 First Quarter Financial Results
Feb 01, 05
08:04 ET	Biopure Acquires Control of Hemopure(R) Marketing and Distribution in South Africa
Jan 10, 05
16:05 ET	Biopure Announces Closing of $11.3 Million Financing
Jan 05, 05
08:41 ET	Biopure to Raise $11.3 Million Through Sale of Common Stock
Dec 16, 04
07:30 ET	Biopure Receives Notice of Nasdaq Listing Requirements
Dec 15, 04
12:06 ET	Biopure Announces Closing of $11.6 Million Financing
Dec 09, 04
08:35 ET	Biopure to Raise $11.6 Million Through Sale of Common Stock and Warrants
Dec 08, 04
07:25 ET	Biopure Announces 2004 Fourth Quarter and Year-End Financial Results
Nov 22, 04
07:30 ET	Biopure Announces Resignation of Senior Vice President
Nov 02, 04
07:31 ET	Dr. Martin B. Leon of the Cardiovascular Research Foundation to Act as Biopure's Chief Medical Director
Oct 12, 04
12:33 ET	Biopure Appoints Jay B. Pieper of Partners Healthcare System to its Board of Directors And Dr. Kenneth Ouriel of the Cleveland Clinic to its Medical Advisory Board
Sep 14, 04
16:40 ET	Biopure Raises $7 Million Through Sale of Common Stock and Warrants
Aug 27, 04
07:30 ET	Biopure Corporation Issues Notice to Stockholders Regarding Proposed Offering of Common Stock and Warrants
Aug 18, 04
07:30 ET	Biopure Announces 2004 Third Quarter Financial Results
Aug 11, 04
16:05 ET	Biopure to Announce Third Quarter 2004 Financial Results on August 18, 2004
07:37 ET	Biopure Announces Proposed Public Offering of Common Stock
Jul 28, 04
07:30 ET	Biopure Initiates Phase II Clinical Trial of Hemopure(R) in Trauma Patients in South Africa
Jun 23, 04
07:30 ET	Biopure Appoints New President and Chief Executive Officer and Restructures the Company
May 20, 04
16:05 ET	Biopure Announces 2004 Second Quarter Financial Results
May 13, 04
07:30 ET	Biopure Announces Second Quarter 2004 Conference Call and Webcast
Apr 30, 04
16:42 ET	Biopure Updates Previously Disclosed Securities and Exchange Commission Inquiry
Mar 25, 04
07:30 ET	Biopure Names Vice President of Clinical Research
Feb 24, 04
13:15 ET	Biopure Announces Resignation of Chief Executive Officer
Feb 19, 04
17:55 ET	Biopure Announces 2004 First Quarter Financial Results and Updates Regulatory and Operating Plans
Jan 08, 04
07:32 ET	Biopure Updates Hemopure(R) Regulatory Status Following FDA Meeting
Dec 24, 03
17:52 ET	Biopure Receives 'Wells Notice' From Securities and Exchange Commission
Dec 22, 03
12:43 ET	Biopure Initiates European Phase II Clinical Trial of Hemopure in Coronary Angioplasty Patients
Dec 11, 03
16:27 ET	Biopure Announces 2003 Fourth Quarter and Year-End Financial Results
Oct 30, 03
08:59 ET	Biopure Updates Regulatory and Operating Plans
Oct 20, 03
16:04 ET	Biopure to Present at Mass Opportunities Biotechnology Investor Conference on October 27, 2003